KRAS Lung Cancer- Hope & The Future of Treatments with Dr Fawzi Abu Rous | Pt 3/3

Two Women Thought They COULDN'T Get Lung Cancer. They Both Did| Ep 1 of 3

"I Googled it. It says poor prognosis. It put me in a really dark place." -Samantha Samantha Murrell and Loryn Fadus are two young women living with HER2 mutated ung cancer. In this first conversation, they sit down with YLCI co-founder Leah Phillips to talk about the road to diagnosis- the missed windows, the misdiagnoses, the shock of hearing "stage four," and what they wish they had known from the start. This is Part 1 of a three-part conversation. Parts 2 and 3 cover treatment decisions, living with HER2 lung cancer, and what community has meant to both of them. Chapters 00:00 [https://www.youtube.com/watch?v=AvlAu65DgPs&list=PLOBC-bEhORaw&index=1] Introduction 00:53 [https://www.youtube.com/watch?v=AvlAu65DgPs&list=PLOBC-bEhORaw&index=1&t=53s] Samantha's first symptoms 02:32 [https://www.youtube.com/watch?v=AvlAu65DgPs&list=PLOBC-bEhORaw&index=1&t=152s] Hearing the diagnosis 03:42 [https://www.youtube.com/watch?v=AvlAu65DgPs&list=PLOBC-bEhORaw&index=1&t=222s] Stage four and an initial prognosis 04:30 [https://www.youtube.com/watch?v=AvlAu65DgPs&list=PLOBC-bEhORaw&index=1&t=270s] Discovering HER2 Exon 20 Mutation through biomarker testing 05:23 [https://www.youtube.com/watch?v=AvlAu65DgPs&list=PLOBC-bEhORaw&index=1&t=323s] "I thought lung cancer was the one I couldn't get" 07:14 [https://www.youtube.com/watch?v=AvlAu65DgPs&list=PLOBC-bEhORaw&index=1&t=434s] Loryn's symptoms and the path to diagnosis 13:44 [https://www.youtube.com/watch?v=AvlAu65DgPs&list=PLOBC-bEhORaw&index=1&t=824s] Learning about HER2 and finding hope 15:02 [https://www.youtube.com/watch?v=AvlAu65DgPs&list=PLOBC-bEhORaw&index=1&t=902s] What to tell your newly diagnosed self 16:02 [https://www.youtube.com/watch?v=AvlAu65DgPs&list=PLOBC-bEhORaw&index=1&t=962s] Misunderstandings about oncogene driven lung cancer 18:32 [https://www.youtube.com/watch?v=AvlAu65DgPs&list=PLOBC-bEhORaw&index=1&t=1112s] What's coming in Part 2 This series is proudly sponsored by Boehringer Ingelheim. YLCI retains full editorial control of all content. ⚠️ Disclaimer This content is for informational purposes only and is not medical advice. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

HER2 Lung Cancer Resistance and Emerging Research With Dr. Kyle Concannon | Ep. 3 of 3

In Part 3 of our HER2-driven lung cancer series, Leah Phillips and thoracic medical oncologist Dr. Kyle Concannon (UC Health, University of Colorado) tackle the harder questions. They get into what resistance actually means, the difference between on-target and off-target resistance, why a cancer can sometimes transform into a different type entirely, and the emerging research and combination approaches being studied for HER2 lung cancer patients. This is a conversation many patients will eventually need to have. The research is moving fast and there is real reason for hope. Thanks to Boehringer Ingelheim for supporting this series. YLCI retains full editorial control. This content is for informational purposes only and is not medical advice. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

HER2 Lung Cancer Treatment & Monitoring With Dr. Kyle Concannon | Ep. 2 of 3

Once you know you have HER2 lung cancer, what comes next? In Part 2 of our HER2-driven lung cancer series, Leah Phillips and thoracic medical oncologist Dr. Kyle Concannon (UC Health, University of Colorado) walk through what treatment actually looks like. They cover how first-line decisions are made for early versus advanced disease, where HER2-targeted therapies fit in, how doctors tell whether a treatment is working, what brain monitoring looks like, and what a progression conversation involves. Whether you're newly diagnosed or supporting someone through treatment, this episode will help you walk into your next oncology appointment more prepared. Thanks to Boehringer Ingelheim for supporting this series. YLCI retains full editorial control. This content is for informational purposes only and is not medical advice. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

What Is HER2 Lung Cancer? With Dr. Kyle Concannon | Ep. 1 of 3

In lung cancer, HER2 can mean different things. In Part 1 of our HER2-driven lung cancer series, Leah Phillips sits down with thoracic medical oncologist Dr. Kyle Concannon (UC Health, University of Colorado) to cover the basics: what a HER2 alteration actually is, the difference between overexpression, amplification, and the exon 20 insertion mutation, why the type matters for treatment, and why next-generation sequencing at diagnosis is non-negotiable. This is Part 1 of 3. Parts 2 and 3 cover treatment and monitoring, then resistance and emerging research. About Dr. Kyle Concannon: Assistant Professor of Medicine-Medical Oncology at the University of Colorado and a thoracic medical oncologist at UCHealth University of Colorado Hospital. Trained as a physician-scientist at MD Anderson, his lab studies why oncogene-driven lung cancers (EGFR, HER2, ALK, ROS1) stop responding to therapy and how to overcome that resistance. He also co-hosts The  @crackingcancer podcast [https://studio.youtube.com/channel/UCFJwUDDzRTkv81Nq8PEuJ3A] https://som.cuanschutz.edu/Profiles/Faculty/Profile/40545 [https://som.cuanschutz.edu/Profiles/Faculty/Profile/40545] This series is proudly sponsored by Boehringer Ingelheim. This is educational content. Not medical advice. Always talk to your own care team about your specific situation.

Lung Cancer: Treatment Decisions, Second Opinions & Side Effect | Mayya's Lung Cancer Story | Pt 3/3

"We put out the fire. This is the last ember." In Part 3, Mayya Grinberg breaks down how she secured a second opinion with one of the world's leading ALK+ specialists before she needed one, how she navigated the radiation decision, and what no one prepared her for when the side effects hit eight weeks later. If you are navigating treatment decisions with a targetable mutation, this one is for you. Chapters: 0:00 [https://www.youtube.com/watch?v=DQY4de-ORlA&list=PLA6NQl_P42YPKcybKcfclhy2tw5qYcmuq&index=6] — Introduction 0:18 [https://www.youtube.com/watch?v=DQY4de-ORlA&list=PLA6NQl_P42YPKcybKcfclhy2tw5qYcmuq&index=6&t=18s] — Getting a second opinion before you need one 1:00 [https://www.youtube.com/watch?v=DQY4de-ORlA&list=PLA6NQl_P42YPKcybKcfclhy2tw5qYcmuq&index=6&t=60s] — Finding Dr. Alice Shaw at Mass General 3:51 [https://www.youtube.com/watch?v=DQY4de-ORlA&list=PLA6NQl_P42YPKcybKcfclhy2tw5qYcmuq&index=6&t=231s] — What the second opinion confirmed 4:19 [https://www.youtube.com/watch?v=DQY4de-ORlA&list=PLA6NQl_P42YPKcybKcfclhy2tw5qYcmuq&index=6&t=259s] — Surgery vs. radiation: how she decided 7:21 [https://www.youtube.com/watch?v=DQY4de-ORlA&list=PLA6NQl_P42YPKcybKcfclhy2tw5qYcmuq&index=6&t=441s] — Radiation Side Effects 9:40 [https://www.youtube.com/watch?v=DQY4de-ORlA&list=PLA6NQl_P42YPKcybKcfclhy2tw5qYcmuq&index=6&t=580s] — Pulmonary PT and recovery ⚠️ Disclaimer This content is for informational purposes only and is not medical advice. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition. 📢 Amplifying the Voices of Young-Onset Lung Cancer Lung cancer is often caught late in young adults because "they're too young." At the Young Lung Cancer Initiative (YLCI), we are changing that narrative. We are a 501(c)(3) nonprofit dedicated to providing support, research, and advocacy for the young-onset community.